Evidence map›Paper›PMID 38723177›Full record

Trial reportThe Journal of infectious diseases2024

Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate.

Kristina E M Persson, Jessica L Horton, Liriye Kurtovic, James S McCarthy, Robin F Anders, James G Beeson

Abstract readClinical Trial, Phase IRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Development of high affinity antibodies toFrontiers in immunology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kristina E M PerssonDepartment of Laboratory Medicine, Lund University, Lund, Sweden.
Jessica L HortonBurnet Institute, Melbourne, Victoria, Australia.
Liriye KurtovicBurnet Institute, Melbourne, Victoria, Australia.
James S McCarthyQIMR-Berghofer Medical Research Institute, QueenslandAustralia.
Robin F AndersDepartment of Biochemistry and Chemistry, La Trobe Institute for Molecular Sciences, La Trobe University, Bundoora, Victoria, Australia.
James G BeesonBurnet Institute, Melbourne, Victoria, Australia.ORCID 0000-0002-1018-7898

Funding

Avtal om Läkarutbildning och ForskningLund UniversityNational Health and Medical Research Council 1173046Region Skåne
6 · The paper itself

Abstract

Maintaining high-affinity antibodies after vaccination may be important for long-lasting immunity to malaria, but data on induction and kinetics of affinity is lacking. In a phase 1 malaria vaccine trial, antibody affinity increased following a second vaccination but declined substantially over 12 months, suggesting poor maintenance of high-affinity antibodies. CLINICAL TRIALS REGISTRATION: Australian New Zealand Clinical Trials Registry ACTRN12607000552482.

Indexed as

Antibodies, ProtozoanAntibody AffinityMalaria, FalciparumMalaria VaccinesPlasmodium falciparumAdolescentAdultAustraliaFemaleHumansMaleMerozoitesVaccinationYoung AdultAntibodies, ProtozoanMalaria Vaccinesaffinity maintenanceantibodyantibody affinitymalariamalaria vaccine

Identifiers

PMID38723177
PMCPMC11420798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.